Clinical Trial Update: Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1 [Phase 3]

View source ↗

Summary

Phase 3 neoadjuvant trial update in triple-negative breast cancer evaluating anti-PD-L1 therapy combined with standard treatment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Invasive Ductal Breast Carcinoma

Snippet

Sponsor: Fondazione Michelangelo | Conditions: Invasive Ductal Breast Carcinoma | Phase 3 | Status: COMPLETED